Vimentin Antibody (YA6418)(PBS only)
(Synonyms: FLJ36605; OTTHUMP00000019224; VIM; VIME_HUMAN; Vimentin.)Vimentin Antibody (YA6418) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Vimentin.
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Product Details
Vimentin Antibody (YA6418) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Vimentin.
-
Calculated Molecular Weight Predicted band size: 53 kDa
affinity purified.
Non-conjugated
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Plays a role in cell directional movement, orientation, cell sheet organization and Golgi complex polarization at the cell migration front (By similarity). Protects SCRIB from proteasomal degradation and facilitates its localization to intermediate filaments in a cell contact-mediated manner (By similarity); Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2
-
Subcellular Localization
Cytoplasm; Cytoplasm, cytoskeleton; Nucleus matrix; Cell membrane
-
Expression
Tissue_specificity:It is highly expressed in fibroblasts, expressed in small amounts in T cells and B cells, and expressed very low or not at all in Burkitt lymphoma cell lines. It is expressed in many hormone-independent breast cancer cell lines.
Induction:Up-regulated by muramyl-dipeptide and lipopolysaccharide -
Subunit
Homomer assembled from elementary dimers (PubMed:20176112). Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with BCAS3 (PubMed:17505058). Interacts with LGSN (By similarity). Interacts with SYNM (By similarity). Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with PLEC isoform 1C (PubMed:24940650). Interacts with STK33 (PubMed:18811945). Interacts with LARP6 (PubMed:21746880). Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton (PubMed:16361107, PubMed:18827015). Interacts with TOR1AIP1 (PubMed:16361107). Interacts with DIAPH1 (PubMed:23325789). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament (PubMed:16923132). Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM (PubMed:29496907). Interacts with NOD2 (PubMed:27812135). Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2) (PubMed:26845719). Interacts with PRKCE (via phorbol-ester/DAG-type 2 domain) (PubMed:18408015). Interacts with BFSP2 (By similarity). Interacts with PPL (By similarity). Interacts (via rod domain) with PKP1 (PubMed:10852826). Interacts with PKP2 (PubMed:10852826). Interacts with SCRIB (via PDZ domains); the interaction protects SCRIB from proteasomal degradation and facilitates SCRIB localization to intermediate filaments, the interaction is reduced by cell contact inhibition (PubMed:19386766)
-
Synonyms
FLJ36605; OTTHUMP00000019224; VIM; VIME_HUMAN; Vimentin.
Powered by Bioz
